spironolactone has been researched along with Heart Failure, Diastolic in 15 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Heart Failure, Diastolic: Heart failure caused by abnormal myocardial relaxation during DIASTOLE leading to defective cardiac filling.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to determine if variants in NR3C2, which codes the target protein of spironolactone, or CYP11B2, which is involved in aldosterone synthesis, were associated with spironolactone response, focused on the primary end point of diastolic function (E/e'), in Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) participants." | 9.41 | NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial. ( Cavallari, LH; Duarte, JD; Dumeny, L; Edelmann, F; Pieske, B; Vardeny, O, 2021) |
| "This study aimed to determine if variants in NR3C2, which codes the target protein of spironolactone, or CYP11B2, which is involved in aldosterone synthesis, were associated with spironolactone response, focused on the primary end point of diastolic function (E/e'), in Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) participants." | 5.41 | NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial. ( Cavallari, LH; Duarte, JD; Dumeny, L; Edelmann, F; Pieske, B; Vardeny, O, 2021) |
| "Eplerenone treatment had no significant impact on any biomarker at 6 months but attenuated the increase in pro-collagen type-III aminoterminal peptide at 12 months (p = 0." | 2.74 | Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. ( Baugh, JA; Dawkins, IR; Ledwidge, MT; Mak, GJ; McDonald, KM; Murphy, NF; Patle, AK; Phelan, DM; Watson, CJ, 2009) |
| "Metabolic syndrome is a highly predisposing condition for cardiovascular disease and could be a cause of excess salt-induced organ damage." | 1.35 | Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. ( Ando, K; Fujita, M; Fujita, T; Kawarazaki, H; Matsui, H; Nagae, A; Nagase, M; Shimosawa, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dumeny, L | 1 |
| Vardeny, O | 1 |
| Edelmann, F | 4 |
| Pieske, B | 4 |
| Duarte, JD | 1 |
| Cavallari, LH | 1 |
| Wachter, R | 3 |
| Schmidt, AG | 2 |
| Kraigher-Krainer, E | 1 |
| Colantonio, C | 1 |
| Kamke, W | 1 |
| Duvinage, A | 1 |
| Stahrenberg, R | 1 |
| Durstewitz, K | 1 |
| Löffler, M | 1 |
| Düngen, HD | 1 |
| Tschöpe, C | 1 |
| Herrmann-Lingen, C | 2 |
| Halle, M | 2 |
| Hasenfuss, G | 2 |
| Gelbrich, G | 2 |
| Cleland, JG | 1 |
| Pellicori, P | 1 |
| Borlaug, BA | 1 |
| Neil, CJ | 1 |
| Singh, S | 1 |
| Frenneaux, M | 1 |
| Milan, A | 1 |
| Abram, S | 1 |
| Veglio, F | 1 |
| Lund, LH | 1 |
| Ståhlberg, M | 1 |
| Voors, AA | 1 |
| Hundertmark, M | 1 |
| Frantz, S | 1 |
| Matsui, H | 1 |
| Ando, K | 1 |
| Kawarazaki, H | 1 |
| Nagae, A | 1 |
| Fujita, M | 1 |
| Shimosawa, T | 1 |
| Nagase, M | 1 |
| Fujita, T | 1 |
| Mak, GJ | 1 |
| Ledwidge, MT | 1 |
| Watson, CJ | 1 |
| Phelan, DM | 1 |
| Dawkins, IR | 1 |
| Murphy, NF | 1 |
| Patle, AK | 1 |
| Baugh, JA | 1 |
| McDonald, KM | 1 |
| Binder, L | 1 |
| Einecke, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Characterization of Myocardial Interstitial Fibrosis and Cardiomyocyte Hypertrophy by Cardiac MRI In Heart Failure: Implication on Early Remodeling and on the Transition to Heart Failure[NCT03084679] | 90 participants (Anticipated) | Interventional | 2017-11-01 | Recruiting | |||
| The Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart Failure[NCT00505336] | 43 participants (Actual) | Interventional | 2006-04-30 | Completed | |||
| Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)[NCT00094302] | Phase 3 | 3,445 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
First incidence of aborted cardiac arrest (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.09 |
| Spironolactone | 0.05 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 4.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 3.1 |
| Spironolactone | 2.8 |
Hospitalization for MI, stroke or the management of heart failure, whichever occurred first (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.2 |
| Spironolactone | 5.5 |
Average post-baseline Chloride, taking into consideration baseline Chloride, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 102.33 |
| Spironolactone | 102.26 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 7.8 |
| Spironolactone | 7.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.6 |
| Spironolactone | 5.9 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
"Average post-baseline depression, taking into consideration baseline depression, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Patient Health Questionnaire (PHQ) is a 10-item, self-administered instrument for screening, diagnosing, monitoring and measuring the severity of depression. Scores can range from 0-27, in which lower scores reflect better mental health status. The PH-Q was administered at the following study visits: baseline, month 12 and annually thereafter. Valid translations of this questionnaire were only available for subjects enrolled in the United States and Canada." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 5.6 |
| Spironolactone | 5.1 |
First incidence of a deterioration of renal function. The TOPCAT protocol defines deterioration of renal function as occurring if a subject has a serum creatinine value which is at least double the baseline value for that subject, and is also above the upper limit of normal (assumed to be 1.0 mg/dL for females and 1.2 mg/dL for males.) (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 2.2 |
| Spironolactone | 3.2 |
First incidence of atrial fibrillation among subjects without a history of atrial fibrillation at baseline (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.4 |
| Spironolactone | 1.4 |
Average post-baseline GFR, taking into consideration baseline GFR, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mL/min/1.73m2 (Least Squares Mean) |
|---|---|
| Placebo | 67.50 |
| Spironolactone | 65.20 |
First incidence of a hospitalization for any reason (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 20.0 |
| Spironolactone | 18.8 |
First incidence of a hospitalization for the management of heart failure (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 3.8 |
First incidence of myocardial infarction (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.2 |
First incidence of new onset diabetes mellitus among subjects without a history of diabetes mellitus at baseline. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.7 |
| Spironolactone | 0.7 |
Average post-baseline Potassium, taking into consideration baseline Potassium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 4.32 |
| Spironolactone | 4.49 |
"Average post-baseline quality of life, taking into consideration baseline quality of life and treatment group.~The McMaster Overall Treatment Evaluation questionnaire is a self-administered 3-item instrument that measures a patient's perception of change in their health-related quality of life since the start of therapy. The questionnaire consists of a single question - Since treatment started, has there been any change in your activity limitation, symptoms and/or feelings related to your heart condition? Scores can range from -7 to +7, and higher scores reflect better health status. The questionnaire was administered at the following study visits: month 4 and month 12. Valid translations of this questionnaire were only available for subjects enrolled in the United States, Canada and Argentina." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.2 |
| Spironolactone | 1.2 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The EuroQOL visual analog scale (EQ5D) is a single-item, self-administered instrument that quantifies current health status. Scores can range from 0-100, in which higher scores reflect better health status. The EQ5D was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 65.9 |
| Spironolactone | 66.4 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The KCCQ was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 63.1 |
| Spironolactone | 64.4 |
Average post-baseline serum creatinine, taking into consideration baseline serum creatinine, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 1.11 |
| Spironolactone | 1.17 |
Average post-baseline Sodium, taking into consideration baseline Sodium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 140.95 |
| Spironolactone | 140.33 |
First incidence of stroke (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 8.3 |
| Spironolactone | 6.8 |
1 review available for spironolactone and Heart Failure, Diastolic
| Article | Year |
|---|---|
[Heart failure: new insights and developments].
Topics: Acute Disease; Aminobutyrates; Biphenyl Compounds; Cardiac Resynchronization Therapy; Combined Modal | 2014 |
4 trials available for spironolactone and Heart Failure, Diastolic
| Article | Year |
|---|---|
NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial.
Topics: Genotype; Heart Failure, Diastolic; Humans; Receptors, Mineralocorticoid; Spironolactone; Treatment | 2021 |
Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
Topics: Aged; Diastole; Double-Blind Method; Echocardiography; Exercise Test; Female; Heart Failure, Diastol | 2013 |
Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone.
Topics: Aged; Aged, 80 and over; Biomarkers; Collagen Type I; Collagen Type III; Echocardiography, Doppler; | 2009 |
Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone.
Topics: Aged; Aged, 80 and over; Biomarkers; Collagen Type I; Collagen Type III; Echocardiography, Doppler; | 2009 |
Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone.
Topics: Aged; Aged, 80 and over; Biomarkers; Collagen Type I; Collagen Type III; Echocardiography, Doppler; | 2009 |
Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone.
Topics: Aged; Aged, 80 and over; Biomarkers; Collagen Type I; Collagen Type III; Echocardiography, Doppler; | 2009 |
Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in pa
Topics: Aldosterone; Diastole; Disease Progression; Diuretics; Double-Blind Method; Exercise Tolerance; Heal | 2010 |
10 other studies available for spironolactone and Heart Failure, Diastolic
| Article | Year |
|---|---|
Defining diastolic heart failure and identifying effective therapies.
Topics: Female; Heart Failure, Diastolic; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolacto | 2013 |
Spironolactone made no difference to patients with mild diastolic heart failure.
Topics: Controlled Clinical Trials as Topic; Diuretics; Heart Failure, Diastolic; Humans; Mineralocorticoid | 2013 |
Heart failure: Aldosterone antagonism for HFpEF.
Topics: Biomarkers; Cardiovascular Agents; Heart Failure, Diastolic; Humans; Mineralocorticoid Receptor Anta | 2013 |
Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Topics: Female; Heart Failure, Diastolic; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolacto | 2013 |
Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Topics: Female; Heart Failure, Diastolic; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolacto | 2013 |
Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Topics: Female; Heart Failure, Diastolic; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolacto | 2013 |
Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply.
Topics: Female; Heart Failure, Diastolic; Humans; Male; Mineralocorticoid Receptor Antagonists; Spironolacto | 2013 |
[Spironolactone not effective in diastolic heart failure].
Topics: Heart Failure, Diastolic; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Spironola | 2014 |
Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder.
Topics: Aldosterone; Animals; Blood Pressure Determination; Disease Models, Animal; Echocardiography, Dopple | 2008 |
[2 promising substances for diastolic heart failure].
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; B | 2012 |